股东批准了捷豹健康的提案，早期试验显示其药物可能帮助患有罕见致命肠道疾病的婴儿。 Shareholders approved Jaguar Health’s proposals, and early trials show its drug may help infants with a rare, fatal intestinal disease.

Jaguar Health Inc.宣布,股东在其2025年12月8日的特别会议上批准了所有三项提案,包括公司治理和战略事项。 Jaguar Health, Inc. announced that shareholders approved all three proposals at its special meeting on December 8, 2025, including corporate governance and strategic matters. 公司报告了一项概念验证试验的初步有希望结果，显示植物衍生药物crofelemer可能通过降低对全静脉支持的依赖度高达37%，从而延长患有微绒毛包围病（MVID）的婴儿存活期，这是一种罕见且致命的肠道疾病，尽管观察到毒性。 The company reported promising early results from a proof-of-concept trial showing crofelemer, a plant-derived drug, may extend survival in infants with microvillus inclusion disease (MVID), a rare, fatal intestinal disorder, by reducing dependence on total parenteral support by up to 37%, though toxicity was observed. 没有针对MVID的经批准的治疗方法。 No approved treatments exist for MVID. 捷于2025年10月2日与FDA举行会议,讨论推进安慰剂对照试验,并寻求加速批准的途径. Jaguar held a meeting with the FDA on October 2, 2025, to discuss advancing a placebo-controlled trial and pursuing an expedited approval pathway. 该公司将Mytesií出售给与艾滋病毒有关的腹泻患者,并经营以胃肠和心理健康治疗为重点的子公司,它计划在2025年12月新兴增长会议上介绍最新情况。 The company, which markets Mytesi® for HIV-related diarrhea and operates subsidiaries focused on gastrointestinal and mental health therapies, plans to present updates at the December 2025 Emerging Growth Conference. 前瞻性声明涉及风险和不确定性。 Forward-looking statements involve risks and uncertainties.